• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Thursday, November 19, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Cancer

YAP and TAZ Hyperactivation May Expose Tumors While Promoting Immune Evasion

by
November 14, 2026
in Cancer, Health
Reading Time: 6 mins read
0
YAP and TAZ Hyperactivation May Expose Tumors While Promoting Immune Evasion

YAP and TAZ Hyperactivation May Expose Tumors While Promoting Immune Evasion

Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

Hyperactive cancer-promoting proteins YAP and TAZ are linked to genomic instability that may make tumor cells more recognizable to immune defenses while simultaneously elevating PD-L2 expression to suppress T-cell destruction, according to a study led by researchers at Hiroshima University and international collaborators. The investigation, published in Communications Biology, evaluated clinical and genomic datasets alongside laboratory cell cultures and mouse tumor models to examine how Hippo pathway disruption influences tumor vulnerability and immune evasion.

Under normal physiological conditions, the Hippo signaling pathway regulates cell growth and restricts the activity of YAP and TAZ through regulatory kinases LATS1 and LATS2. When LATS1 and LATS2 are lost or impaired, this molecular restraint weakens, permitting YAP and TAZ activity to rise. Although hyperactive YAP and TAZ have established roles in driving malignant tumor growth, their specific contributions to modulating antitumor immune responses have previously remained less defined.

In laboratory experiments focusing on head and neck squamous cell carcinoma, researchers observed that elevated YAP and TAZ activity directly drove increased expression of PD-L2. To evaluate whether PD-L2 actively shielded tumor cells from immune destruction, investigators exposed head and neck cancer cells to engineered T cells specifically designed to target the epidermal growth factor receptor present on the malignant cells.

The experimental assays demonstrated that cancer cells lacking LATS1 and LATS2 resisted destruction by the engineered T cells. However, when researchers selectively removed PD-L2 from these resistant cells, the cancer cells became significantly more vulnerable to T-cell assault, indicating that PD-L2 expression contributed directly to tumor evasion of targeted immune activity.

The study also evaluated the parallel consequences of Hippo pathway disruption on tumor genomic stability. In laboratory models, the loss of LATS1 and LATS2 coincided with elevated YAP and TAZ activity, heightened genomic instability, and an accumulation of somatic mutations and DNA damage, characteristics that can render cancer cells more readily recognizable to CD8+ T cells.

To determine the precise transcriptional mechanism connecting YAP and TAZ to immune suppression, the research team analyzed the regulatory machinery governing PD-L2 transcription. Their experiments identified critical roles for the transcription factor TEAD, the epigenetic reader BRD4, and a specific super-enhancer element, demonstrating that disruption of these components attenuated YAP/TAZ-driven PD-L2 expression in experimental models.

In addition to cell and animal assays, the researchers analyzed clinical and genomic records from a cohort of 1,662 patients with various advanced cancers who had received immune checkpoint inhibitor therapy. The analysis sought to evaluate whether Hippo pathway alterations correlated with therapeutic responses and long-term outcomes following checkpoint blockade.

Within the patient dataset, tumors harboring alterations in selected Hippo pathway genes, including FAT1, NF2, LATS1, LATS2, and YAP1, demonstrated significantly higher mutation counts and elevated tumor mutational burden. Patients with these gene alterations exhibited improved overall survival after immune checkpoint inhibitor therapy compared to patients whose tumors lacked the alterations.

The authors noted key methodological limitations, emphasizing that clinical dataset observations reflect statistical associations rather than direct evidence of causality. Because the retrospective patient records provided genomic, mutational burden, and survival metrics without directly measuring YAP/TAZ activation, PD-L2 levels, or immune-cell infiltration within the same tumor tissues, the clinical role of the laboratory-observed mechanism remains unproven.

The findings may offer specific insights for head and neck squamous cell carcinoma, a malignancy where response rates to immune checkpoint inhibitor monotherapy currently remain below 20 percent. Corresponding author Toshinori Ando noted that Hippo pathway alterations and YAP/TAZ hyperactivation may hold potential as prognostic factors for patient stratification, though independent clinical cohorts with matched molecular and microenvironmental data are required to confirm clinical utility.

The central paradox identified by the investigators hinges on how malignant cells can simultaneously draw immune surveillance and defend against immune destruction. In their published findings, the researchers observed that elevated activity of cancer promoting proteins YAP and TAZ creates two opposing biological conditions inside developing tumors. Hyperactive YAP and TAZ accompany pronounced genomic instability and elevated DNA damage, generating abnormal alterations that allow CD8+ T cells to recognize the cancer cells. Simultaneously, this heightened activity stimulates increased production of PD-L2, which binds to inhibitory PD-1 receptors on CD8+ T cells and suppresses their attack. Because the immune system detects tumor cells yet fails to destroy them, researchers suggested this balance explains why tumors with Hippo pathway alterations may respond better when checkpoint inhibitor therapies block those inhibitory signals.

To clarify the origins of this regulatory imbalance, the researchers examined the normal supervisory role of the Hippo signaling pathway. Under ordinary physiological conditions, the Hippo pathway serves as a critical growth control system that keeps YAP and TAZ from operating unchecked. Key regulatory kinases within this pathway, specifically LATS1 and LATS2, maintain constant restraint over YAP and TAZ activity. However, when cancer cells experience loss of LATS1 and LATS2, this molecular restraint weakens, permitting YAP and TAZ activity to increase. While earlier investigations had established that overactive YAP and TAZ promote cancer growth, their role in helping tumors evade immune attack had remained far less clear.

To test whether elevated PD-L2 expression protects malignant cells from immune assault, the research team designed targeted cell culture experiments focusing on head and neck squamous cell carcinoma. The investigators challenged these cancer cells with engineered T cells designed to recognize EGFR, a protein on the cancer cells. When exposed to these engineered immune cells, cancer cells lacking LATS1 and LATS2 resisted the targeted T-cell attack. However, when the scientists selectively removed PD-L2, the cancer cells became significantly more vulnerable to destruction. This outcome indicated that PD-L2 contributed directly to the ability of LATS1/2-deficient cells to evade attack by engineered T cells.

In parallel with these immune evasion measurements, the investigators explored the genomic consequences accompanying the loss of LATS1 and LATS2. Their laboratory models revealed that the resulting hyperactivation of YAP and TAZ was accompanied by increased genomic instability, elevated DNA damage, and more mutations in tumor cells. This accumulation provides a biological mechanism for enhanced immune recognition, because genome instability and elevated DNA damage may make cancer cells more recognizable to CD8+ T cells. Thus, the molecular changes promoting tumor growth and PD-L2 expression also render malignant cells more recognizable to CD8+ T cells, establishing a vulnerability that immune therapies might exploit.

The research team also investigated the detailed molecular machinery through which YAP and TAZ stimulate PD-L2 expression. Through targeted laboratory experiments, the authors demonstrated that this transcriptional upregulation relies on interactions involving TEAD and BRD4, together with a super-enhancer involved in regulating PD-L2. When the researchers disrupted these molecular components within experimental models, YAP/TAZ-driven PD-L2 expression was reduced. This demonstration points to possible therapeutic strategies targeting TEAD, BRD4, or the super-enhancer to limit PD-L2 expression, though authors noted such approaches require further testing.

Although detailed mechanistic work focused on head and neck squamous cell carcinoma, the study combined experiments across multiple cancer-cell types with mouse tumor models.

To evaluate how these biological mechanisms align with human clinical experiences, the researchers analyzed clinical and genomic records from a cohort of 1,662 patients with several types of advanced cancer who received immune checkpoint inhibitor therapy. The analysis revealed that tumors harboring alterations in selected Hippo pathway genes—specifically FAT1, NF2, LATS1, LATS2, and YAP1—carried significantly more mutations and exhibited higher tumor mutational burden than tumors without those alterations.

Despite these positive statistical associations, the researchers emphasized crucial limitations regarding the scope of their clinical findings. The authors did not demonstrate that the laboratory-observed relationships among YAP/TAZ activation, genomic instability, and PD-L2-mediated immune evasion actually caused the improved survival observed in those patients. While the clinical dataset included genomic information, tumor mutational burden, and survival metrics, it did not directly measure YAP/TAZ activation, PD-L2 expression, or immune-cell infiltration within the same patient tumors. Because these measurements were absent from the patient records, the proposed mechanistic explanation remains a plausible hypothesis rather than a proven causal sequence in clinical cohorts.

The clinical relevance of these findings is underscored by challenges in treating head and neck squamous cell carcinoma, where response rates to immune checkpoint inhibitor monotherapy remain below 20 percent. In current practice, anti-PD-1 antibodies block the PD-1 receptor on T cells, preventing PD-L2 from binding and acting as an inhibitory brake, which helps restore T-cell activity. Importantly, anti-PD-1 treatment itself was not tested in the laboratory experiments conducted for this study. Corresponding author Toshinori Ando stated that cancer patients harboring mutations regulating the Hippo pathway and YAP/TAZ hyperactivation may be sensitized to immune checkpoint inhibitor therapy owing to genome instability and PD-L2 expression. Ando and colleagues noted that Hippo pathway alterations and YAP/TAZ hyperactivation may have potential as prognostic factors for stratifying patients receiving checkpoint inhibitors, though further studies using independent patient cohorts with matched molecular and tumor microenvironment data remain necessary.

Subject of Research: Hippo pathway dysregulation, YAP/TAZ hyperactivation, and tumor immune evasion mechanisms

Article Title: Cancer-promoting proteins may make tumors easier to spot but also help them evade immune attack

Article References: Cancer-promoting proteins may make tumors easier to spot but also help them evade immune attack. Original publication (Bibliographic details unavailable.)

Image Credits: AI Generated

DOI: Not provided

Keywords: YAP, TAZ, Hippo signaling pathway, PD-L2, immune checkpoint inhibitors, head and neck squamous cell carcinoma, genomic instability, CD8+ T cells, LATS1, LATS2, tumor mutational burden, TEAD, BRD4, FAT1, NF2, Hiroshima University, immunotherapy

News Source: Nathaniel Bowman. (November 14, 2026). YAP and TAZ Hyperactivation May Expose Tumors While Promoting Immune Evasion. Scienmag.

Tags: BRD4CD8+ T cellsFAT1genomic instabilityhead and neck squamous cell carcinomaHippo signaling pathwayHiroshima UniversityImmune checkpoint inhibitorsimmunotherapyLATS1LATS2NF2PD-L2TAZTEADtumor mutational burdenYAP
Share12Tweet7Share2ShareShareShare1

Related Posts

Nurse-Led Telecoaching Reduces Nutritional Risk and Distress in Gynaecological Cancer

Nurse-Led Telecoaching Reduces Nutritional Risk and Distress in Gynaecological Cancer

November 19, 2026
Sentinel Surveillance Reveals Influenza and SARS-CoV-2 Trends in Iraq

Sentinel Surveillance Reveals Influenza and SARS-CoV-2 Trends in Iraq

November 19, 2026

Esketamine Patient-Controlled Analgesia Reduces Dynamic Pain After Laparoscopic Sleeve Gastrectomy

November 19, 2026

Fungal Infections Identified in Non-ICU Pneumonia Patients Without Classic Immunosuppression

November 19, 2026

POPULAR NEWS

  • Electrical Nerve Stimulation Reduces Acute Postoperative Pain Following Knee Replacement

    Electrical Nerve Stimulation Reduces Acute Postoperative Pain Following Knee Replacement

    29 shares
    Share 12 Tweet 7
  • Thermodynamic Kinetic Modeling Unifies Ammonia Desorption Across Titanium Silicalite-1 Zeolites

    29 shares
    Share 12 Tweet 7
  • Elevated Waist-to-Height Ratio and HbA1c Linked to Higher Cardiovascular Disease Risk

    29 shares
    Share 12 Tweet 7
  • Silver-Functionalized Chitosan Nanoparticles Enhance Platelet-Rich Plasma for Canine Wound Healing

    29 shares
    Share 12 Tweet 7

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Smart Maintenance Method Enables Automatic Failure Detection in Displacement Pumps

Regional Epigenetic Clock Calibration Narrows Biological Age Advantage in Nicoya Blue Zone

Nurse-Led Telecoaching Reduces Nutritional Risk and Distress in Gynaecological Cancer

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 88 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.